Fig. 3: Changes in target lesion size. | British Journal of Cancer

Fig. 3: Changes in target lesion size.

From: The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study

Fig. 3

a Best percentage change in target lesion size over time and b waterfall plot showing best percentage change from baseline in patients treated with AZD7648 monotherapy. c Best percentage change in target lesion size over time and d waterfall plot showing best percentage change from baseline in patients treated with AZD7648 and PLD. a *New lesion. The reference line at +20% represents the definition of progressive disease. The reference line at −30% represents the definition for confirmed partial response. Three patients with no post baseline assessment are excluded. b BID twice daily, PD best response of progressive disease, QD once daily, SD best response of stable disease. #Value capped as a result of the restriction to the Y axis scale (−100%, +100%). Increase was 108.33%. Best percentage change in target lesion size is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction. The reference line at +20% represents the definition of progressive disease. The reference line at −30% represents the definition for confirmed partial response. Three patients with no post baseline assessment are excluded. c *New lesion. The reference line at +20% represents the definition of progressive disease. The reference line at −30% represents the definition of confirmed partial response. Four patients with no post baseline assessment are excluded. d Four patients with no post baseline assessment are excluded. ‡Value capped as a result of the restriction to the Y axis scale (−100%, +100%). Increase was 334.7%. BID twice daily, PD best response of progressive disease, PR best response of partial response, QD once daily, SD best response of stable disease.

Back to article page